glp 1 for cardiovascular disease The Effects of GLP-1 on Health How GLP-1 Medications Reduce Heart

88,89,90,91 A notable study using a porcine model of MI revealed that treatment with adeno-associated virus serotype 6 encoding miR-199a (AAV6-miR-199a) significantly improved overall and regional contractility, increased the myocardial mass, and reduced the scar size

Last month, we announced a strategic shift in our US weight loss business that reflects the market transformation in FDA-approved GLP-1 treatments

For currently approved GLP-1 receptor agonists available for weight management in the UK, NICE has established specific eligibility criteria: Semaglutide (Wegovy) NICE TA875 recommends semaglutide for adults with: A body mass index (BMI) of 35 kg/m or above with at least one weight-related comorbidity (such as hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease), or A BMI of 3034.9 kg/m with at least one weight-related comorbidity, prescribed only in specialist weight management services Evidence of previous unsuccessful weight loss attempts through diet, physical activity, and behavioural interventions Treatment is limited to a maximum of 2 years Liraglutide (Saxenda) NICE TA664 recommends liraglutide for adults with: A BMI of 35 kg/m or above (with or without comorbidities), or A BMI of 3034.9 kg/m with at least one weight-related comorbidity Evidence of previous unsuccessful weight loss attempts Treatment is limited to a maximum of 2 years Both medications must be prescribed as part of a specialist weight management service providing multidisciplinary support, including dietary advice, physical activity programmes, and behavioural interventions

The PGD is the final authority on eligibility

5 In addition to the potential benefits of GLP-1 receptor agonists already mentioned, several dedicated cardiovascular outcome trials have reported positive cardiovascular and kidney outcomes with agents from the GLP-1 receptor agonist class